Advertisement

Picture EBD Group Whitepaper State of Innovation in Europe 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 8393 | Ordered by Date (descending)
1 2 3 ... 82 83 84  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Novartis–Astellas: micafungin, 202110– acquisition of ww product rights to Mycamine/Funguard by Sandoz from Astellas SIGNED 2023-01-24
DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-19
DeuterOncology–Investsud: investment, 202301 financing round Series A toatlling €5.65m incl new investor Investsud Tech 2023-01-19
DeuterOncology–Newton Biocapital: investment, 202301 financing round Series A toatlling €5.65m incl existing investor Newton Biocapital 2023-01-19
DeuterOncology–Noshaq: investment, 202301 financing round Series A toatlling €5.65m incl new investor Noshaq 2023-01-19
DeuterOncology–SEVERAL: investment, 202301 financing round Series A €5.65m with Newton Biocapital + Noshaq + Investsud Tech 2023-01-19
Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems 2023-01-18
Blackford Analysis–Bayer: investment, 202301– acquisition by Bayer ANNOUNCED 2023-01-18
Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems 2023-01-18
InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital 2023-01-17
InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership 2023-01-17
InDevR–SEVERAL: investment, 202301 financing round Series B $9m from bioMérieux + Adjuvant Capital 2023-01-17
Mérieux–InDevR: VaxArray platform, 202301– excl distribution of VaxArray portfolio by bioMérieux in Europe 2023-01-17
Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery 2023-01-11
Boehringer–Minapharm: rec protein production technology, 202301– collab non-excl €na of ProBioGen + Boehringer on DirectedLuck transposase technology 2023-01-10
NextPoint Therapeutics–Bayer: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Leaps by Bayer 2023-01-10
NextPoint Therapeutics–Catalio Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Catalio Capital Management 2023-01-10
NextPoint Therapeutics–Harvard Univ: investment, 202301 financing round Series B totalling $80m incl existing + co-investor Binney Street Capital 2023-01-10
NextPoint Therapeutics–Invus Group: investment, 202301 financing round Series B totalling $80m incl new + co-investor Invus 2023-01-10
NextPoint Therapeutics–MPM Capital: investment, 202301 financing round Series B totalling $80m incl existing + co-investor MPM Capital Management 2023-01-10
NextPoint Therapeutics–PagodaTree Partners: investment, 202301 financing round Series B totalling $80m incl new + co-investor PagodaTree Partners 2023-01-10
NextPoint Therapeutics–PERSON: investment, 202301 financing round Series B totalling $80m incl existing + co-investor + co-founder Gordon Freeman 2023-01-10
NextPoint Therapeutics–Sanofi: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Sanofi Ventures 2023-01-10
NextPoint Therapeutics–SEVERAL: investment, 202301 financing round Series B $80m co-led by Leaps by Bayer + Sanofi Ventures 2023-01-10
NextPoint Therapeutics–Sixty Degree Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Sixty Degree Capital 2023-01-10
Albireo–Ipsen: investment, 202301– cash tender offer $952m at $42/share plus 1 CVR/share entitling to $10/CVR 2023-01-09
Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform 2023-01-09
Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea 2023-01-09
Evosep–Novo Group: investment, 202301 minority investment of $40m by Novo Holdings A/S 2023-01-09
Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO 2023-01-09
Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash 2023-01-09
Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED 2023-01-08
Acquifer Imaging–Bruker: investment, 202201 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker 2023-01-05
Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners 2023-01-05
Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute 2023-01-05
Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners 2023-01-05
Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP 2023-01-05
BioVersys–AMR Action Fund: investment, 202301 financing round Series C extension with CHF8.2m? from AMR AF bringing total Series C to CHF32.6m 2023-01-05
ErVaccine–BPCE: investment, 202301 seed financing round totalling €4.5m (incl non-dilutive funds) incl investor Seventure 2023-01-05
ErVaccine–France (govt): investment, 202301 seed financing round totalling €4.5m (incl non-dilutive funds) incl investor Bpifrance 2023-01-05
ErVaccine–SEVERAL: investment, 202301 seed financing round €4.5m (incl non-dilutive funds) with Seventure + Bpifrance 2023-01-05
Volta Medical–Gilde Investment: investment, 202301 fianncing round Series B totalling €36m incl existing + co-investor Gilde Healthcare 2023-01-05
Volta Medical–Lightstone Ventures: investment, 202301 fianncing round Series B totalling €36m incl new + co-investor Lightstone Ventures 2023-01-05
Volta Medical–SEVERAL: investment, 202301 fianncing round Series B €36m led by Vensana Capital 2023-01-05
Volta Medical–Vensana Capital: investment, 202301 fianncing round Series B totalling €36m incl new + lead investor Vensana Capital 2023-01-05
Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker 2023-01-04
Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties 2023-01-04
Cellectis–EU (govt): credit, 202212– credit facility up to €40m in 3 tranches from EIB to develop allogeneic CAR T-cell products 2022-12-28
Affibody–EU (govt): credit, 202212– venture debt loan facility €20m from EIB supported by InvestEU programme 2022-12-22
Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED 2022-12-22
Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB 2022-12-20
Numares–SEVERAL: investment, 202212 financing round €20m from existing investors 2022-12-20
Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties 2022-12-19
S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG 2022-12-16
Minervax–Adjuvant Capital: investment, 202212 financing round totalling €22m incl exisiting + co-investor Adjuvant Capital 2022-12-15
Minervax–Bellevue: investment, 202212 financing round totalling €22m incl new + co-lead investor Pureos Bioventures 2022-12-15
Minervax–EU (govt): credit, 202212 loan facility €50m from EIB 2022-12-15
Minervax–LF Investment: investment, 202212 financing round totalling €22m incl exisiting + co-investor LF Investment 2022-12-15
Minervax–Novo Group: investment, 202212 financing round totalling €22m incl exisiting + co-investor Novo REPAIR Impact Fund 2022-12-15
Minervax–Sanofi: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sanofi Ventures 2022-12-15
Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures 2022-12-15
Minervax–Sunstone Life Science: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sunstone Life Science Ventures 2022-12-15
Minervax–Sweden (govt): investment, 202212 financing round totalling €22m incl exisiting + co-investor Industrifonden 2022-12-15
Minervax–Trill Impact: investment, 202212 financing round totalling €22m incl new + co-lead investor Trill Impact Ventures 2022-12-15
Minervax–Wellington Partners: investment, 202212 financing round totalling €22m incl exisiting + co-investor Wellington Partners 2022-12-15
ExeVir Bio–EU (govt): credit, 202212– venture debt financing €25m from EIB for develoment of nanobody Covid-19 therapy 2022-12-14
Ono Pharmaceutical–PrecisionLife: drug target discovery, 202212– collab r+d drug targets + biomarker discovery for CNS drugs 2022-12-14
Storm Therapeutics–Cambridge Innovation Capital: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor CIC 2022-12-14
Storm Therapeutics–Fast Track Initiative: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor FTI 2022-12-14
Storm Therapeutics–IP Group: investment, 202212 financing round Series B totalling $30m incl existing + co-investor IP Group plc 2022-12-14
Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures 2022-12-14
Storm Therapeutics–Otsuka: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Taiho Ventures LLC 2022-12-14
Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures 2022-12-14
Storm Therapeutics–Seroba: investment, 202212 financing round Series B totalling $30m incl existing + co-investor Seroba Life Sciences 2022-12-14
Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC 2022-12-14
Storm Therapeutics–Univ Tokyo: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor UTokyo IPC 2022-12-14
BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures 2022-12-13
BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures 2022-12-13
BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health 2022-12-13
BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises 2022-12-13
BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises 2022-12-13
BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital 2022-12-13
BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures 2022-12-13
Green Bioactives–Javelin Ventures: investment, 202212 seed financing round totalling £2.6m incl lead investor Eos Advisory LLP 2022-12-13
Green Bioactives–Milltrust International: investment, 202212 seed financing round totalling £2.6m incl co-investor Green Earth Ventures Fund 2022-12-13
Green Bioactives–Regenerate Ventures: investment, 202212 seed financing round totalling £2.6m incl co-investor RV Agtech Fund 2022-12-13
Green Bioactives–Scotland (govt): investment, 202212 seed financing round totalling £2.6m incl co-investor Scottish Enterprise 2022-12-13
Green Bioactives–SEVERAL: investment, 202212 seed financing round £2.6m led by Eos Advisory LLP 2022-12-13
Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand 2022-12-13
Chr. Hansen–Novozymes: investment, 202212– merger acquisition valuing Chr Hansen at DKK660.55/share ANNOUNCED 2022-12-12
Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share 2022-12-12
Bico–Sartorius: investment, 202212– directed share issue SEK487m (€45m) to existing investor Sartorius resulting 10.1% share + 8.5% of voting rights 2022-12-08
MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM 2022-12-08
Sartorius–Bico: laboratory equipment, 202212– collab RnD 3D cell printing technologies + digital soluitons for cell line development workflows 2022-12-08
Sartorius–Bico: laboratory equipment, 202212– distribution of Bico products in APAC region by Sartorius 2022-12-08
Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices 2022-12-06
Entact Bio–SEVERAL: investment, 202212 financing round Series A $81m co-led by Qiming Venture Partners USA + venBio Partners 2022-12-06
Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck 2022-12-01
BioNTech–Ryvu Therapeutics: small molecule immuno modulators, 202211– collab + license €20m upfront + research funding + milestones + royalties 2022-11-30
Ryvu Therapeutics–BioNTech: investment, 202211 equity investment €20m in connection with collab + license agreement by BioNTech 2022-11-30
1 2 3 ... 82 83 84  next pagenext page



Advertisement

Picture [iito] No Tracking 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

» top